
OXFORD BIODYNAMICS PLC — Investor Relations & Filings
Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Holding(s) in Company | 2026-03-30 | English | |
| Holding(s) in Company | 2026-03-20 | English | |
| OBD to present at PMWC 2026 | 2026-03-03 | English | |
| Change of Nominated Adviser | 2026-02-17 | English | |
| Group of companies' accounts made up to 2025-09-30 | 2026-02-07 | English | |
| Holding(s) in Company | 2026-01-27 | English |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 33090381 | Holding(s) in Company | 2026-03-30 | English | ||
| 32999131 | Holding(s) in Company | 2026-03-20 | English | ||
| 32870571 | OBD to present at PMWC 2026 | 2026-03-03 | English | ||
| 28145821 | Change of Nominated Adviser | 2026-02-17 | English | ||
| 46825992 | Group of companies' accounts made up to 2025-09-30 | 2026-02-07 | English | ||
| 13423399 | Holding(s) in Company | 2026-01-27 | English | ||
| 13336071 | Result of AGM | 2026-01-26 | English | ||
| 13321261 | Board Change | 2026-01-26 | English | ||
|
2025
7 filings
| |||||
| 10596208 | Publication of 2025 Annual Report | 2025-12-22 | English | ||
| 10182820 | Preliminary Results and Notice of AGM | 2025-12-16 | English | ||
| 9703457 | Notice of Results | 2025-12-09 | English | ||
| 9132673 | Statement re share price, update on EpiSwitch PSE | 2025-12-03 | English | ||
| 8620070 | Holding(s) in Company | 2025-11-25 | English | ||
| 8250005 | Holding(s) in Company | 2025-11-12 | English | ||
| 8213853 | Holding(s) in Company | 2025-11-11 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for OXFORD BIODYNAMICS PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Nautilus Biotechnology, Inc.
Develops a proteome analysis platform to quantify proteins …
|
NAUT | US | Professional, scientific and te… |
|
NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno…
|
950220 | US | Professional, scientific and te… |
|
Neovacs
Biotech firm developing immunotherapies and investing in Bi…
|
ALNEV | FR | Professional, scientific and te… |
|
NervGen Pharma Corp.
Clinical-stage biotech developing treatments to promote ner…
|
NGEN | CA | Professional, scientific and te… |
|
NEUREN PHARMACEUTICALS LIMITED
Develops innovative therapies for rare neurodevelopmental d…
|
NEU | NZ | Professional, scientific and te… |
|
NEURIZON THERAPEUTICS LIMITED
Clinical-stage developer of mTOR modulators for ALS and neu…
|
NUZ | AU | Professional, scientific and te… |
|
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
Develops peptide-based therapeutics for neurodegenerative a…
|
NSB | AU | Professional, scientific and te… |
|
NEUROTECH INTERNATIONAL LIMITED
Clinical-stage biopharmaceutical company developing pediatr…
|
NTI | AU | Professional, scientific and te… |
|
NewAmsterdam Pharma Co N.V.
A clinical-stage biopharma developing therapies for metabol…
|
NAMS | NL | Professional, scientific and te… |
|
NEXALIS THERAPEUTICS LTD
Develops small molecule therapies for chronic inflammatory …
|
NX1 | AU | Professional, scientific and te… |
OXFORD BIODYNAMICS PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7829/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7829 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7829 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7829 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7829}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OXFORD BIODYNAMICS PLC (id: 7829)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.